Immune Checkpoint Blockade Combined with AbnobaViscum® Therapy Is Linked to Improved Survival in Advanced or Metastatic Non-Small-Cell Lung Cancer Patients: A Registry Study in Accordance with the ESMO Guidance for Reporting Real-World Evidence

Schad, Friedemann; Thronicke, Anja; Hofheinz, Ralf-Dieter; Klein, Reinhild; Grabowski, Patricia; Oei, Shiao Li; Wuestefeld, Hannah; Grah, Christian

dc.contributor.author	Klein, Reinhild
dc.date.accessioned	2025-05-05T08:13:19Z
dc.date.available	2025-05-05T08:13:19Z
dc.date.issued	2024
dc.identifier.issn	1424-8247
dc.identifier.uri	http://hdl.handle.net/10900/165028
dc.language.iso	en	de_DE
dc.publisher	Basel : Mdpi	de_DE
dc.relation.uri	http://dx.doi.org/10.3390/ph17121713	de_DE
dc.subject.ddc	540	de_DE
dc.subject.ddc	610	de_DE
dc.title	Immune Checkpoint Blockade Combined with AbnobaViscum® Therapy Is Linked to Improved Survival in Advanced or Metastatic Non-Small-Cell Lung Cancer Patients: A Registry Study in Accordance with the ESMO Guidance for Reporting Real-World Evidence	de_DE
dc.type	Article	de_DE
utue.quellen.id	20250203000000_00304
utue.personen.roh	Schad, Friedemann
utue.personen.roh	Thronicke, Anja
utue.personen.roh	Hofheinz, Ralf-Dieter
utue.personen.roh	Klein, Reinhild
utue.personen.roh	Grabowski, Patricia
utue.personen.roh	Oei, Shiao Li
utue.personen.roh	Wuestefeld, Hannah
utue.personen.roh	Grah, Christian
dcterms.isPartOf.ZSTitelID	Pharmaceuticals	de_DE
dcterms.isPartOf.ZS-Issue	Article 1713	de_DE
dcterms.isPartOf.ZS-Volume	17 (12)	de_DE
utue.fakultaet	04 Medizinische Fakultät	de_DE